Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2009
05/05/2009US7528151 Heterocyclic urea derivatives for the treatment of pain
05/05/2009US7528150 Urea derivatives having vanilloid receptor antagonist activity
05/05/2009US7528149 e.g. N-[1-(2-aminoethyl)-4-piperidinyl]-7-methyl-3-(8-quinolinylmethyl)-3H-imidazo[4,5-b]pyridin-2-amine tetrahydrochloride trihydrate; immunostimulant; lower respiratory tract illness during infancy and childhood, asthma, pneumonia
05/05/2009US7528148 Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors
05/05/2009US7528147 e.g. 2 {5,6-dimethoxy-1-[2-(4-methylpiperazin- 1 -yl)ethyl]-1H-indol-3 -yl}-1H-pyrrolo[2,3- b]pyridine; Insulin Growth Factor-1 (somatomedin) antagonist; antiproliferative, antitumor agent; solid tumor; prostate, lung and breast cancer
05/05/2009US7528146 Substituted 1H-pyrrolo[2,3-b]pyridines and preparation thereof
05/05/2009US7528145 Administering rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid or 42-O-(2-hydroxy)ethyl rapamycin for therapy of fibroids
05/05/2009US7528144 N-alkyl-4-amino-1,8-naphthalimides; to visualize, monitor or detect biomolecules; detecting cholesterol trafficking or cholesterol rich domains; INSTANTLYSO LLT-1; no significant cytotoxicity; photostability; very fluorescent in both water and membrane milieu
05/05/2009US7528143 JAK family of protein tyrosine kinases inhibitors; N4-(4-Methoxy-phenyl)-N2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyrimidine-2,4-diamine; angiogenic-associated disorders including solid tumors and cancer, eye disease, inflammation, psoriasis, viral infection; antiproliferative agents
05/05/2009US7528142 Aminopyrimidines useful as kinase inhibitors
05/05/2009US7528141 Use of cyclopenta[g]quinazoline derivatives for treating cancer
05/05/2009US7528140 Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors
05/05/2009US7528139 Sulfonamides
05/05/2009US7528138 Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
05/05/2009US7528137 Compounds, compositions, and methods
05/05/2009US7528136 Prolinamide derivatives as NK3 antagonists
05/05/2009US7528135 Pyridine derivatives as H3 antagonists
05/05/2009US7528134 Acetamides and benzamides that are useful in treating sexual dysfunction
05/05/2009US7528133 Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
05/05/2009US7528132 immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds
05/05/2009US7528131 Substituted morpholinyl compounds
05/05/2009US7528130 Cytotoxic agents comprising taxanes and their therapeutic use
05/05/2009US7528129 CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
05/05/2009US7528128 Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof
05/05/2009US7528127 Short-acting benzodiazepines
05/05/2009US7528126 viricides, parasiticide, bactericides, gene therapy and treating cisplatin refractory disease; e.g. 1,1'[[(Propane-1,3-diyl)dioxy]bis(11aS)-11-sulpho-7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4-benzodiazepin-5-one]] sodium salt
05/05/2009US7528125 Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
05/05/2009US7528124 1,3-dihydro-2H-indol-2-one derivative
05/05/2009US7528123 Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
05/05/2009US7528122 2-Methylene-19,26-dinor-1 alpha ,25-dihydroxyvitamin D3; psoriasis; leukemia, cancer, multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; decrease the calcemic effect while retaining the ability to suppress parathyroid hormone
05/05/2009US7528121 Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate
05/05/2009US7528120 phosphoric acid mono-[2-hydroxymethyl-4-(4-octyl-phenyl)-2-(1-oxo-1,3-dihydro-isoindol-2-yl)-butyl] ester; disorders mediated by lymphocytes interactions like transplant rejection, graft versus host disease, autoimmune diseases; binding affinity to Sphingosine-1-phosphate(S1P) receptors
05/05/2009US7528119 Administering to a mammal P1,P4-di(uridine 5'-)tetraphosphate, tetralithium salt; or P1,P4-di(uridine 5'-)tetraphosphate, tetrapotassium salt; in a pharmaceutically acceptable carrier to treat dry eye or retinal detachment
05/05/2009US7528118 RNAi modulation of ApoB and uses thereof
05/05/2009US7528116 Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
05/05/2009US7528115 Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines
05/05/2009US7528113 Method and composition for the treatment of adenoviral ocular infections
05/05/2009US7528106 Angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor; peptide, pegaptanib sodium, EMD 472523; antiangiogenic drugs
05/05/2009US7527952 Crystals of inosine monophosphate dehydrogenase/oxidized inosine monophosphate thiomidate intermediate/mycophenolic acid (IIMPDH/XMP*/MPA)
05/05/2009US7527936 Modulators of angiogenesis
05/05/2009US7527808 Stability and dissolvability; for the therapy of an infectious disease
05/05/2009US7527800 Influenza hemagglutinin and neuraminidase variants
05/05/2009US7527786 Monoclonal anti-idiotypic antibody; antitumor agents; anticarcinogenic agents; antiproliferative agents; immunotherapy; hormone antagonist therapy
05/05/2009CA2622696A1 Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
05/05/2009CA2537402C Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
05/05/2009CA2448281C Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
05/05/2009CA2436260C Compositions containing a ruthenium(iii) complex and a heterocycle
05/05/2009CA2417764C Highly absorbable solid preparations containing sitafloxacin and tartaric acid
05/05/2009CA2403352C Use of comt inhibitors as analgesics
05/05/2009CA2391440C Process for enhancing canine and feline reproductive performance
05/05/2009CA2347863C Treatment of disorders of the outer retina
05/05/2009CA2345521C Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
05/05/2009CA2323419C Bactericide
05/05/2009CA2322953C Pyridine derivative and pharmaceutical containing the same
05/05/2009CA2314942C Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
05/05/2009CA2311450C Pharmaceutical aerosol compositions
05/05/2009CA2274116C Use, of an inhibitor of thioredoxin, for inhibiting tumor growth
05/05/2009CA2267247C Heteroaryloxyethylamines as 5-ht1a ligands
05/05/2009CA2265774C Antibacterial composition
05/05/2009CA2247675C Antifungal agents
05/05/2009CA2234980C Cyclopeptide derivatives
05/05/2009CA2204747C New azo derivatives of 5-aminosalicylic acid
05/05/2009CA2173338C Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
05/05/2009CA2166394C Improved nicotine lozenge and therapeutic method for smoking cessation
05/05/2009CA2149298C Flk-1 is a receptor for vascular endothelial growth factor
05/05/2009CA2146647C Treatment of autoimmune and inflammatory disorders
05/01/2009CA2606828A1 Methods of assessing and treating pulmonary disease
04/2009
04/30/2009WO2009055828A1 New tetracyclic compounds
04/30/2009WO2009055788A1 Pneumoreductive therapy and compositions useful therein
04/30/2009WO2009055749A1 2-aminooxazole derivatives as trpvl antagonists useful for treating pain
04/30/2009WO2009055734A1 Condensed compounds with activity at estrogen receptors
04/30/2009WO2009055730A1 Process for making thienopyrimidine compounds
04/30/2009WO2009055696A1 CARBACEPHEM β-LACTAM ANTIBIOTICS
04/30/2009WO2009055675A1 Methods of identifying histone deacetylase inhibitors useful for neurological disorders
04/30/2009WO2009055674A1 Pyrrolopyrimidine alkynyl compounds and methods of making and using same
04/30/2009WO2009055671A1 Compositions and methods for treating cystic fibrosis
04/30/2009WO2009055633A1 Hydrated crystalline esters of camptothecin for the treatment of cancer
04/30/2009WO2009055631A1 Calcilytic compounds
04/30/2009WO2009055571A2 Methods of treating pulmonary disorders using liposomal vancomycin formulations
04/30/2009WO2009055568A2 Liposomal vancomycin formulations
04/30/2009WO2009055562A1 Tubulysins and processes for preparing
04/30/2009WO2009055557A1 Process for the preparation of macrolide antibacterial agents
04/30/2009WO2009055548A1 Arylindenopyrimidines and their use as adenosine a2a receptor antagonists
04/30/2009WO2009055506A2 Aminoflavone (nsc 686288) and combinations thereof for treating breast cancer
04/30/2009WO2009055445A2 RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
04/30/2009WO2009055437A2 (1,4-diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone ligands for nicotinic acetylcholine receptors, useful for the treatment of disease
04/30/2009WO2009055418A1 Pyridosulfonamide derivatives as pi3 kinase inhibitors
04/30/2009WO2009055357A1 Diazepane compounds which modulate the cb2 receptor
04/30/2009WO2009055331A2 Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
04/30/2009WO2009055308A1 Arylindenopyrimidines and their use as adenosine a2a receptor antagonists
04/30/2009WO2009055299A1 Substituted pyrimidine-5-carboxamide and 5-carboxylic ester kinase inhibitors
04/30/2009WO2009055289A2 Therapeutic substituted lactams
04/30/2009WO2009055084A2 Vitamin c compositions
04/30/2009WO2009055077A1 Tropane compounds
04/30/2009WO2009055059A1 Methods for treating substance dependence
04/30/2009WO2009055053A2 Diarylhydantoin compounds as androgen receptor modulators
04/30/2009WO2009055044A1 Enhancement of plant growth
04/30/2009WO2009055038A1 Pharmaceutical formulation of clavulanic acid
04/30/2009WO2009055033A1 Pyrazolo-pyridinone derivatives and methods of use
04/30/2009WO2009055021A1 Methods and compositions for treating hepatic diseases